Selected Publications

Koopman LA, Alemdehy F, dr Poot SAH, Paauwe M, Wang W, Epstein K, van den Brink E, Gorlani A, Verzijl D, Brandhorst M, Franken P, Vries LS, Gielen E, Plantinga TS, Houtkamp M, Engelberts PJ, Egerog FL, Thalhauser CJ, Bosgra S, Gitto SB, Powell DJ Jr, Gamse JT, Overdijk MB, Breiji ECW: Preclinical comparison of two CD3xB7H4 bispecific antibodies for solid tumor therapy reveals CD3 affinity-dependent potency and tolerability tradeoffs. Molecular Cancer Therapeutics June 2026 Notes: Provisionally Accepted.

Gitto SB, Hughes S, Paul M, Bom S, Burchett R, Morreale BG, Pannucci A, Rono C, Weigel C, Wolf CL, Williams JE Jr, Cohn W, Gibson H, Dolatshahi S, Gupta A, Rutkowshi MR, Anderson KG: Opportunities to enhance cancer research through advocate-researcher partnerships. Cancer Research June 2026.

Gitto SB, Riad A, McArthur A, Babazada H, Nakkina S, Simpkins F, Mankoff DA, Mach RH, Farwell MD: PARP-targeted theranostic approach to image and treat ovarain cancer. Jounral of Nuclear Medicine 67: 262154-262154, May 2026.

Kinose Y, Xu H, Kim H, Wang X, Kumar S, Shan X, George E, Medvedev S, Ortiz A, Gitto SB. Whicker M, D’Andrea K, Wubbenhost B, Hallberg D, O’Connor M, Schwartz L, Hwang W, Nathanson KL, Mills G, Velculescu VE, Wang T, Brown E, Drapkin R, Simpkins F: Target clear cell ovarian cancers with ARID1A loss by combination inhibition of BRD4 and ATR. Molecular Cancer Therapeutics October 2025.

Onecha VV, Gitto SB, Riad A, Farwell MD, Pryma DA, Bertolet A: A monte carlo dosimetry-based cell survival model incorporating spatial and temporal heterogeneity for RPT preclinical studies: TU-730-209-2. Medical Physics 52: e70059479, October 2025.

Nakkina SP, Medvedev S, Ma K, Anderson M, Simpkins F, Powell DJ Jr., Gitto SB: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.

Riad A, McAuthur A, Babazada H, Mankoff D, Mach RH, Farwell FD, Gitto SB: Preclinical evaluation of PTT, an At-211-labeled rucaparib analogue, as a therapeutic agent for cancer therapy. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.

Gitto SB, Riad A, McArthur A, Simpkins F, Pryma DA, Farwell MD: PARP-targeted alpha therapy for the treatment of PARP-inhibitor resistant ovarian cancer. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.

Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Farwell MD.: PARP1-targeted alpha therapy enhances target expression. European Journal of Nuclear Medicine and Molecular Imaging 15(1): 63, June 2025.

Onecha VV, Suarez-Garcia D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A.: Space- and time-defined Monte Carlo dosimetry explains ovarian cancer cell viability in targeted a-particle therapy with astatine 211-ParaThanatrace. International Journal of Radiation Oncology, Biology, and Physics June 2025.